Targeted extracellular degradation of LRP8 promotes ferroptosis in cancer cells

This study demonstrates that using bispecific cytokine receptor-targeting chimeras (KineTACs) to induce targeted extracellular degradation of the selenium uptake receptor LRP8 effectively depletes the ferroptosis-protective enzyme GPX4, thereby sensitizing cancer cells to ferroptosis and offering a novel strategy to overcome therapy resistance.

The Gist

Imagine cancer cells as a group of very stubborn burglars trying to break into a house (your body). To survive, these burglars have built a super-strong, self-repairing shield around themselves. This shield is made of special materials that stop them from rusting and falling apart—a process scientists call ferroptosis. As long as this shield is intact, the burglars can't be stopped by normal defenses.

The paper describes a clever new way to take down this shield, not by attacking the shield directly, but by cutting off the supply line for the materials needed to build it.

Here is how the process works, step-by-step:

1. The Supply Door (LRP8)
The burglars (cancer cells) need a specific ingredient called selenium to keep their anti-rust shield working. To get this ingredient, they use a special "delivery door" on their surface called LRP8. Think of LRP8 as a dedicated mail slot that only accepts packages containing selenium. Without this door, the burglars can't get the materials they need to maintain their shield.

2. The "Trojan Horse" Trick (KineTACs)
The researchers created a new tool called a KineTAC. You can think of this as a high-tech, two-sided glue trap.

• Side A sticks to the delivery door (LRP8) on the cancer cell.
• Side B sticks to a "trash chute" inside the cell (a cytokine receptor pathway that usually sends things to the cell's recycling center, the lysosome).

When the KineTAC attaches, it tricks the cell into grabbing the delivery door and dragging it straight into the trash chute.

3. The Trash Chute (Lysosome)
Once the delivery door (LRP8) is dragged inside, the cell's internal trash compactor (the lysosome) destroys it. It's like the burglars' mail slot is ripped out of the wall and thrown into a shredder.

4. The Shield Crumbles (GPX4 and Ferroptosis)
With the delivery door gone, the burglars can no longer get selenium. This causes a chain reaction:

• They run out of selenium.
• They can no longer build a key protective enzyme called GPX4 (imagine this as the main bricklayer of their anti-rust shield).
• Without GPX4, their shield falls apart.
• The cancer cells begin to "rust" from the inside out and die. This is ferroptosis.

The Big Picture
The main takeaway is that the researchers found a way to target the outside of the cancer cell (the delivery door) to change what happens inside the cell (the production of protective enzymes). By destroying the door that brings in nutrients, they successfully reprogrammed the cancer cell's survival strategy, forcing it to collapse.

In short: Instead of trying to break the shield, they removed the factory's only delivery truck, causing the factory to run out of parts and shut down.

Technical Summary

Technical Summary: Targeted Extracellular Degradation of LRP8 Promotes Ferroptosis in Cancer Cells

Problem Statement
Cancer cells frequently exhibit a heightened reliance on antioxidant defense mechanisms to survive oxidative stress, creating a specific therapeutic vulnerability known as ferroptosis—a form of regulated cell death driven by iron-dependent lipid peroxidation. Despite this vulnerability, current strategies to therapeutically disable these antioxidant systems, particularly the key protective enzyme glutathione peroxidase 4 (GPX4), remain limited. The challenge lies in effectively reducing GPX4 levels without off-target toxicity or inducing compensatory resistance mechanisms.

Methodology
The authors developed a novel therapeutic approach centered on the targeted degradation of the low-density lipoprotein receptor-related protein 8 (LRP8), a critical receptor for selenium uptake. Selenium is an essential micronutrient required for the synthesis of selenoproteins, including GPX4.

To achieve this, the study utilized bispecific cytokine receptor-targeting chimeras (KineTACs). These engineered molecules function by simultaneously binding to LRP8 on the cell surface and a specific cytokine receptor. This dual binding recruits the LRP8-cytokine receptor complex to internalization pathways that direct the cargo to the lysosome for degradation. This strategy effectively bypasses intracellular protein degradation mechanisms, instead leveraging extracellular receptor-mediated endocytosis to deplete LRP8.

Key Results

• Selective LRP8 Degradation: The KineTACs successfully directed LRP8 to the lysosome, resulting in a significant reduction of LRP8 protein abundance on the cell surface and within the cell.
• Downstream Selenoprotein Depletion: The degradation of LRP8 impaired cellular selenium uptake, leading to a marked decrease in the abundance of multiple selenoproteins. Crucially, this included a substantial reduction in GPX4 levels.
• Sensitization to Ferroptosis: The depletion of GPX4 lowered the cellular threshold for lipid peroxidation. Consequently, cancer cells treated with LRP8-targeting KineTACs became highly sensitized to ferroptosis, demonstrating increased cell death in response to ferroptosis-inducing conditions compared to controls.

Key Contributions

1. Identification of a Targetable Node: The study establishes receptor-mediated selenium uptake via LRP8 as a critical and targetable node in the mechanism of ferroptosis resistance.
2. Novel Degradation Mechanism: It demonstrates that extracellular protein degradation can be effectively leveraged to reprogram intracellular translational dependencies. By targeting a nutrient receptor, the approach indirectly but potently depletes essential intracellular enzymes (like GPX4) that are difficult to target directly.
3. Therapeutic Platform: The work validates the use of KineTACs as a platform for inducing targeted degradation of surface receptors to modulate intracellular metabolic states.

Significance and Claims
The paper claims that this work provides a framework for exploiting nutrient acquisition pathways to overcome therapy resistance in cancer. By linking the extracellular degradation of a nutrient receptor to the intracellular depletion of a key antioxidant enzyme, the authors propose a new strategy to disable the antioxidant defenses that protect tumor cells. The findings suggest that targeting the supply chain of essential nutrients (selenium) via receptor degradation offers a viable alternative to direct enzyme inhibition for inducing ferroptosis in cancer therapy.